Navigation Links
'Disprin Plus' is now 'Disprin Paracetamol'

Reckitt Benckiser has deferred the launch of 'Disprin CV' (cardiovascular) following the confusion over the name of its new painkiller 'Disprin Plus', the company's Regional Director , Mr. Pranab Barua said. The company also announced a change in the brand-name 'Disprin Plus' to 'Disprin Paracetamol'. Subsequent to the launch of Disprin Plus, there were reports citing instances of concern from doctors and consumers regarding the use of the suffix 'Plus' along with the brand-name, Mr. Barua said.

"This matter was also taken up by the drug aythorities and the company was advised to address this concern.// Taking cognisance of the concern of consumers and the drug authorities, the company decided to change the suffix from 'Plus' to 'Paracetamol', thereby making clear the brand's ingredient ," he said.

Mr. Barua said that the company, which had an inventory of 15 - 20 million tablets worth about Rs 1 crore, will suffer loss of sale for a month during the transition period to the tune of Rs 1.5 - 2 crore. Disprin 'Paracetamol' will be in the market by mid-December , he said. The company has also decided not to give any brand push to Disprin Cold and Flu for similar reasons, Mr. Baura said.

Paracetamol-based Disprin 'Plus' was launched by Reckitt Benckiser (India) in August this year to replace Disprin (350 mg aspirin) in the pain relief segment. Mr. Barua said Disprin CV (100 mg aspirin) will not be launched till the new brand 'Disprin Paracetamol' is completely established.


'"/>




Page: 1

Related medicine news :

1. FDA approves new device to treat womens bleeding disorder
2. FDA approves drug for rare liver disease
3. FDA approves first pocket-sized EKG machine
4. FDA approves Watson Pharmaceuticals Oxytrol patch
5. Indian Health Ministry approves sale of Emergency contraceptives as over the counter drug
6. Madras High Court Disapproves of Comparative Advertisements
7. FDA approves Phase 0 trial which tests experimental drugs on humans
8. FDA approves CLARINEX-D 12 HOUR for seasonal allergic rhinitis
9. Study disapproves a new Asthma inhaler
10. GMC Disapproves Internet Doctor
11. New spray gel heals surgical wounds
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/22/2017)... Boca Raton, FL (PRWEB) , ... January 22, 2017 , ... ... products to customers across the world, recently met with big-name retail buyers at the ... strong scientific evidence of efficacy and uses the utmost safety standards in all of ...
(Date:1/21/2017)... Raton, FL (PRWEB) , ... January 21, 2017 , ... ... eRaiser, recently attended the January ECRM Trade Show in Hilton Head, SC, where it ... international reputation for the quality of its beauty and wellness products. At this trade ...
(Date:1/21/2017)... ... ... Seamild, the largest manufacturer of oats in China, is now aiming at global business ... recognized globally as one of the healthiest cereals, XieQingkui, the founder of Seamild, strongly ... to sow the seed of good karma. Buddhism spirit featuring benevolence and sacrifice are ...
(Date:1/21/2017)... , ... January 21, 2017 , ... ... Redwood Family Dermatology has recently joined their multi-specialty medical group. The dermatology ... of cosmetic services. , “We’re excited to add this excellent dermatology practice to ...
(Date:1/21/2017)... ... 21, 2017 , ... The Nobel Biocare™ dental implant company ... for its creos™ line of bone regenerative products. Specifically, the Nobel ... utilizes creos™ allo.gain™ bone graft for a variety of bone reconstruction procedures. In ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... Januar 2017  ResMed (NYSE: RMD ), ... Medical ( Winter Haven, Florida ) gaben ... die Beilegung aller globalen Rechtsstreitigkeiten zwischen den Parteien geeinigt ... ihrer bestehenden Produkte im Tausch gegen Lizenzgebühren an ResMed ... leisten, um das in Florida ...
(Date:1/22/2017)... DAVOS, Switzerland and ABU DHABI , ... leaders from the US ... , Hospital of the Future , at ... in the hospital of the future will be driven by big data and ... better," according to the panel of experts that discussed the ,Hospital of the ...
(Date:1/21/2017)... Mass. , Jan. 20, 2017 /PRNewswire/ ... Keystone Symposia Conference, "PI3K Pathways in Immunology, ... Inc. (NASDAQ: INFI ) ... immuno-oncology development candidate that selectively inhibits phosphoinositide-3-kinase-gamma ... able to help overcome resistance to checkpoint ...
Breaking Medicine Technology: